Mar 9, 2021
As well as being more than a year behind global rivals in developing COVID-19 vaccines, Japanese drugmakers are scrambling to catch up with international competitors in their search for brand new medicines for the disease, highlighting the country’s uphill battle toward gaining the upper hand over the pandemic.
In November, the U.S. Food and Drug Administration granted emergency use authorization to antibody therapy bamlanivimab, developed by an American drugmaker Eli Lilly, marking the world’s first approval of a new drug specifically developed to treat COVID-19. The same month, the FDA also gave the green light to an antibody treatment developed by U.S. biotech firm Regeneron Pharmaceuticals Inc.
Japan drugmakers struggle to keep pace in COVID-19 medicine development japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.
Global Digital photography Market Analysis 2021 Trends, Industry Growth, Opportunities Forecast To 2026 texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Australia began its mass COVID-19 vaccine programme, while the United States approached a staggering half-million deaths despite a recent decline in cases with president Joe Biden planning to memorialize the lives lost.
Factbox: Latest on the worldwide spread of the coronavirus metro.us - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from metro.us Daily Mail and Mail on Sunday newspapers.